TrkA Kinase Inhibitors for Selective Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, inflammation, cancer, and neurodegenerative diseases often fail to effectively target the Trk/neutrophin pathway, leading to inadequate relief and potential side effects, while existing therapies may not fully address the underlying mechanisms of dysmyelination and demyelination disorders.
Innovation Solution
Development of substituted six-membered aryl or heteroaryl benzamide compounds that act as Trk kinase inhibitors, specifically targeting TrkA, to modulate NGF-driven biological responses and inhibit Trk kinases, thereby treating conditions associated with pain, inflammation, cancer, and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Trk inhibitors are used, then pain relief is achieved, but side effects occur and mechanism precision is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that target TrkA receptors with high selectivity. The substituted six-membered aryl or heteroaryl benzamide compounds are engineered to interact specifically with TrkA's binding site, providing localized inhibition at the receptor level while minimizing off-target effects on other kinase pathways, thus reducing side effects while maintaining pain relief effectiveness.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters of the benzamide compounds, including substituent types at positions R1-R6, heteroatom configurations, and steric properties. These parameter modifications optimize the compounds' binding affinity and selectivity for TrkA, enabling precise control over the inhibition mechanism to achieve effective pain relief with reduced harmful effects.
2Adaptability or versatility
If existing therapies are used, then treatment is provided, but mechanism precision is insufficient for underlying mechanisms
Solution Approach 1:
The patent applies segmentation by dividing the Trk receptor family into specific targets, focusing primarily on TrkA while considering TrkB and TrkC. The benzamide compounds are designed to segment the inhibition action specifically against TrkA-mediated pathways, allowing precise targeting of NGF-driven biological responses while maintaining the ability to address multiple conditions through selective TrkA modulation.
Solution Approach 2:
The patent uses the benzamide compounds as intermediary substances that mediate between the TrkA receptor and downstream signaling pathways. These compounds act as selective inhibitors that block the TrkA-NGF interaction, serving as a precise mechanism to interrupt dysmyelination and demyelination processes while maintaining treatment coverage for various conditions including pain, inflammation, and neurodegenerative diseases.
Data Source
AI summary
The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.